Quantum BioPharma

Quantum BioPharma

Quantum BioPharma Announces the Success of unbuzzd™ Clinical Trial

NASDAQ: QNTM | CSE: QNTM | FRA: 0K91 | Upstream: QNTM Overview Quantum BioPharma Ltd. announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism, according to the company. According to the

Quantum BioPharma

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

NASDAQ: QNTM | CSE: QNTM | FRA: 0K91 Overview Quantum BioPharma Ltd. announced its financial and operational results for the second quarter of 2026, ended June 30, 2026, according to the company. As of June 30, 2026, the company's combined cash and cash equivalents, and digital assets, totaled approximately US$

Quantum BioPharma

Quantum BioPharma Receives FDA Clearance to Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis

NASDAQ: QNTM | CSE: QNTM | FRA: 0K91 Overview Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the company to advance its patented, first-in-class multiple sclerosis program